• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2012 Product Image

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2012

  • Published: December 2012
  • 98 pages
  • Global Markets Direct

Gastroesophageal (GE) Junction Carcinomas – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gastroesophageal READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Gastroesophageal (GE) Junction Carcinomas Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Gastroesophageal (GE) Junction Carcinomas 9
Gastroesophageal (GE) Junction Carcinomas Therapeutics under Development by Companies 11
Gastroesophageal (GE) Junction Carcinomas Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Gastroesophageal (GE) Junction Carcinomas Therapeutics – Products under Development by Companies 18
Gastroesophageal (GE) Junction Carcinomas Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Gastroesophageal (GE) Junction Carcinomas Therapeutics Development 20
Bristol-Myers Squibb Company 20
F. Hoffmann-La Roche Ltd. 21
Amgen Inc. 22
AstraZeneca PLC 23
Eli Lilly and Company 24
Exelixis, Inc. 25
Synta Pharmaceuticals Corp. 26
Ascenta Therapeutics, Inc. 27
Gastroesophageal (GE) Junction Carcinomas – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
ipilimumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MT-110 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
cabozantinib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
litronesib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ganetespib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
varlitinib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CPT-11 + Mitomycin C - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Oxaliplatin + Xeloda + Cetuximab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cetuximab + Paclitaxel + Carboplatin + Radiation Therapy - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
sorafenib tosylate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AZD8931 + Paclitaxel - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AZD-4547 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BMS-833923 + Cisplatin + Capecitabine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ZD6474 + Carboplatin + Paclitaxel + 5-Fluorouracil + Radiation Therapy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 58
Oxaliplatin + Epirubicin + Capecitabine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 60
Cisplatin + Irinotecan + Radiation Therapy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
gefitinib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Cetuximab + Cisplatin + Epirubicin + Fluorouracil - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Capecitabine + Carboplatin + Docetaxel + Radiation Therapy - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AMG-386 + Cisplatin + Capecitabine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
AT-101 + Docetaxel + 5-Fluorouracil + Radiotherapy - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 71
Cetuximab + Cisplatin + Docetaxel - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MK-2206 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
mFOLFOX6 + MetMab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 75
Gastroesophageal (GE) Junction Carcinomas Therapeutics – Drug Profile Updates 76
Gastroesophageal (GE) Junction Carcinomas Therapeutics – Discontinued Products 93
Gastroesophageal (GE) Junction Carcinomas Therapeutics - Dormant Products 94
Gastroesophageal (GE) Junction Carcinomas – Product Development Milestones 95
Featured News & Press Releases 95
May 16, 2012: Amgen Presents Results From Exploratory Biomarker Analysis Of Rilotumumab 95
Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University 96
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 98
Disclaimer 98

List of Tables
Number of Products Under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2012 9
Products under Development for Gastroesophageal (GE) Junction Carcinomas – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Bristol-Myers Squibb Company, H2 2012 20
F. Hoffmann-La Roche Ltd., H2 2012 21
Amgen Inc., H2 2012 22
AstraZeneca PLC, H2 2012 23
Eli Lilly and Company, H2 2012 24
Exelixis, Inc., H2 2012 25
Synta Pharmaceuticals Corp., H2 2012 26
Ascenta Therapeutics, Inc., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Gastroesophageal (GE) Junction Carcinomas Therapeutics – Drug Profile Updates 76
Gastroesophageal (GE) Junction Carcinomas Therapeutics – Discontinued Products 93
Gastroesophageal (GE) Junction Carcinomas Therapeutics – Dormant Products 94

List of Figures
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2012 9
Products under Development for Gastroesophageal (GE) Junction Carcinomas – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos